Key facts
- This page summarizes James E. Levine's Form 3 filing for KAZIA THERAPEUTICS LTD (KZIA).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 15 Jun 2026, 18:52.
James E. Levine - 01 Jun 2026 Form 3 Insider Report for KAZIA THERAPEUTICS LTD (KZIA)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- KZIA
- Reported as of
- 01 Jun 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 15 Jun 2026, 18:52:42 UTC
- Prior SEC filing
- 13 Mar 2025
- Next SEC filing
- 23 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Levine
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James E. Levine filed Form 3 for KAZIA THERAPEUTICS LTD (KZIA) on 15 Jun 2026.
Change
- Previous filing in this sequence was filed on 13 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001463151
Primary reporting owner
Levine James E.
- Relationship
- Chief Financial Officer
- Address
- THREE INTERNATIONAL TOWERS, LEVEL 24, 300 BARANGAROO AVE, SYDNEY, NSW, AUSTRALIA
- Signature
- /s/ James Levine
- Signature date
- 15 Jun 2026
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.
SEC remarks
Exhibit 24 - Power of Attorney